Table 1.
COPD prevalence dataa
| Criteria used to define COPD | Country (sample size) | Study population | Ageb (yr) | Prevalence (%) |
|---|---|---|---|---|
| Symptomsc | ||||
| Cerveri et al., 2003 [15] | Italy (18,645) | General population | 20-44 | 9.5 |
| Huchon et al., 2002 [16] | France (14,076) | General population | ≥25 | 4.1 |
| Cerveri et al., 2001 [17] | 16 countries (14,819) | General population | 20-44 | 2.6 |
| Physician reports | ||||
| Cazzola et al., 2009 [18] | Italy (15,229) | General population | NS | 2.5 |
| Schirnhofer et al., 2007 [19] | Austria (1,258) | General population | ≥40 | 5.6 |
| Montnemery et al., 2006 [20] | Sweden (3,692) | General population | 20-59 | 3.6 |
| Hedman et al., 1999 [21] | Finland (3,102) | General population | 18-65 | 3.7 |
| Montnemery et al., 1998 [22] | Sweden (8,469) | General population | 20-59 | 4.6 |
| Lundback et al., 1991 [23] | Sweden (6,610) | General population | 35-66 | 4.1 |
| Functional respiratory tests | ||||
| Miravitlles et al., 2009 [24] | Spain (4,274) | General population | 56.6 (10.7) | 10.2 |
| Van Durme et al., 2009 [25] | Netherlands (7,983) | General population | ≥55 | 11.6 |
| Hansen et al., 2008 [26] | Denmark (4,757) | General population | 45-84 | 12.0 |
| Bednarek et al., 2008 [27] | Poland (1,960) | Primary care | 56.7 (11.6) | 9.3 |
| Roche et al., 2008 [28] | France (4,764) | Health prevention center | 59.9 (10.1) | 2.6 |
| Buist et al., 2007 [8] | Austria (1,258) | General population | ≥40 | 26.1d |
| Germany (683) | 13.3 | |||
| Poland (526) | 22.1 | |||
| Norway (638) | 18.8 | |||
| Shahab et al., 2006 [29] | United Kingdom (8,215) | General population | 55.5 (13.5) | 13.3 |
| Stavem et al., 2006 [30] | Norway (1,619) | Occupational cohort | 49.8 (5.5) | 16.4 |
| Sichletidis et al., 2005 [31] | Greece (6,112) | General population | 21-80 | 5.6 |
| Murtagh et al., 2005 [32] | Ireland (2,484) | General population | 53.3 (8.6) | 6.3 |
| Tzanakis et al., 2004 [33] | Greece (888) | General population | ≥35 | 8.4 |
| Hasselgren et al., 2001 [34] | Sweden (4,814) | General population | 43 (14.8) | 2.1 |
| Peña et al., 2000 [35] | Spain (3,978) | General population | 40-69 | 9.1 |
| Viegi et al., 2000 [36] | Italy (1,727) | General population | ≥25 | 11.0 or 18.3 |
| Jaen et al., 1999 [11] | Spain (497) | General population | 20-70 | 7.2 |
| Dickinson et al., 1999 [37] | United Kingdom (353) | General population | 68.25 | 9.9 |
| Marco Jordán et al., 1998 [12] | Spain (460) | General population | 40-60 | 6.8 |
| Renwick & Connolly, 1996 [38] | United Kingdom (783) | General practitioner | 66.1 | 9.0 |
| Brotons et al., 1994 [13] | Spain (642) | General population | 35-65 | 6.4 |
| Bakke et al., 1991 [39] | Norway (1,275) | General population | 42 (16.1) | 4.5 |
| Models | ||||
| Peabody et al., 2005 [40] | Spain | Total population | ≥30 | 6.2 |
| Norway | 6.3 | |||
| Poland | 6.7 | |||
| Feenstra et al., 2001 [41] | Netherlands | Total population | ≥20 | 1.5 |
| Stang et al., 2000 [42] | Spain | Total population | ≥45 | 10.3 |
| Italy | 11.1 | |||
| France | 10.4 | |||
| United Kingdom | 15.0 |
aPrevalence estimates are based on symptoms (cough and sputum at least 3 months each year), physician reports, functional respiratory tests (FEV1/FVC ratio <70%, FEV1 <80% of predicted, FEV1/FVC ratio <65%, FEV1/FVC ratio <70% or FEV1/FVC ratio <88% (male)/89% (female)) and models (general population). bAge was reported in various ways distinguished here as follows: "≥ x", minimum age; "x" or "x (y)", mean age or mean age (SD); "x-y", age range i.e. min-max. cThese patients had chronic bronchitis. dThese data are also reported in Schirnhofer et al., 2007 [19]. Abbreviations used: COPD, chronic obstructive pulmonary disease; NS, not specified; FEV1, maximum expiratory volume in 1 second; FVC, forced vital capacity.